Hormonal therapy remains the cure of very first option for metastatic individuals with endocrine-responsive breast most cancers (LoE 1a A, AGO ++). The sequential use with the obtainable medication is determined by the individual pretreatment. Reassessment of ER, PR, and HER2 in tumor tissue at